Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 1998

View Archived Issues

Genzyme General expands cardiovascular gene therapy program

AltaRex: Q1 1998 highlights

Company Profile: Link Technology

DuPont Merck and Cytogen continue Quadramet collaboration

CNI-1493 prevents IL-2 toxicity without affecting antitumor activity in rats

Reduction of colon cell proliferation associated with soy product consumption

Bristol-Myers Squibb presents derivatives of indolopyrrolocarbazoles as antitumor agents

Neurokinin antagonists for bronchoconstriction, neurogenic inflammation

Biomira's lymphoma vaccine headed for phase I testing

Newly discovered toxic protein may trigger onset of Alzheimer's disease

Therapeutic Antibodies: Q1 1998 highlights

A-127722 reduces ischemic lesion size in rat model of focal cerebral ischemia

KCB-328: electrophysiological effects of novel class III antiarrhythmic

Techniclone restructures TNT development joint venture

New antiplatelet agents prepared by Sankyo/Ube researchers

Optison launched in Europe

New tachykinin antagonists patented by Pfizer

Preparation and use of MMP/TNF production inhibitors described by Pfizer

Final results of ECST presented

Avonex now available in Canada

New 5-HT2C antagonists presented by Syntex

EP3-selective prostanoid from Ono affords cardioprotection in rabbit MI model

New antiepileptic compounds described by Portela

Matrix receives patent protection for MPI-5020 and AccuSite

Early- and late-phase cardioprotective effects demonstrated for OPC-6535 in pig model

Review study finds mesalamine most effective treatment for ulcerative colitis

Aphton describes efficacy of Gastrimmune at two major scientific meetings

FDA advisory committee recommends approval of Avakine for Crohn's disease

Somatostatin analogue TT-232 prevents proliferation of pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...